



## SF-295 Cells

---

**Catalog #:** SF001

**Cell #:** >5x10<sup>5</sup> cells

**Storage:** Liquid Nitrogen until ready for culture.  
While Culturing keep in 37°C CO<sub>2</sub> incubator

**Product Format:** Frozen Vial

---

### GENERAL INFORMATION

SF-295 cells are human glioblastoma cancer cells. SF-295 were derived from undifferentiated glioblastoma in a 67 year old female. It is recommended to culture these cells following the protocols described below. SF-295 cells have a minimum of 15 population doubling levels when cultured using our protocol.

*Product is for Research use only.*

Frozen Vials are shipped in a Dry Ice Package.

### STATEMENT

Handling human tissue derived products is potentially bio-hazardous, despite testing negative for HIV, HBV, and HCV DNA. Nonetheless, proper precautions must be taken to avoid inadvertent exposure.

### SPECIAL NOTES:

- We strongly advise our customers to use medium and related products recommended by Neuromics, because our cells were grown and adapted using our products.
- The growth featured of our cells can not be guaranteed if the specific growth mediums stated in our datasheets are not used.
- Due to the sensitive nature of primary cells and cell lines, all quality related issues about the cells must be reported back to us within one month after receiving the products. Cells will not be replaced after the one-month period.

### CHARACTERIZATION OF THE CELLS

1. Cytoplasmic VWF/Factor VIII >95% positive by immunofluorescence
2. Cytoplasmic uptake of Di-I-Ac-LDL >95% positive by immunofluorescence
3. Cytoplasmic PECAM1 >95% positive by immunofluorescence

### HANDLING OF ARRIVING CELLS

When you receive the dry ice package with cells in frozen vials, transfer the frozen vials of cells into a -80°C freezer for short period storage or a liquid nitrogen tank for long-term storage.

#### FOR RESEARCH USE ONLY

NEUROMICS REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. v1-09809

[www.neuromics.com](http://www.neuromics.com)

Neuromics Antibodies • 5325 West 74<sup>th</sup> Street, Suite 8 • Edina, MN 55439  
phone 866-350-1500 • fax 612-677-3976 • e-mail [pshuster@neuromics.com](mailto:pshuster@neuromics.com)

## STR PROFILE

<b>Markers:</b>	
Amelogenin	X
CSF1PO	10, 13
D2S1338	15, 20
D3S1358	16, 18
D5S818	11, 12
D7S820	9, 13
D8S1179	13, 14
D13S317	10
D16S539	12, 13
D18S51	15, 18
D21S11	28, 30
FGA	22, 25
Penta D	13, 14.4
Penta E	5, 7
TH01	9.3 (Cosmic-CLP) 9.3, 10
TPOX	8, 11
vWA	16, 17

## STR PROFILE

<b>Class I:</b>	
HLA-A	A*01:01:01,26:01
HLA-B	B*07:02:01,55:01
HLA-C	C*03,07
<b>Class II:</b>	
HLA-DP	DPB1*04:01
HLA-DQ	DQB1*05:03:01,06:02
HLA-DR	DRB1*14,15

## PROTOCOL FOR THAWING THE CELLS AND SUBCULTURE

**Note:** If you have any questions or need clarification regarding the protocol for culturing these cells, please reach out to Dr. Jensen Auguste at (978) 608-1766 with your questions before beginning.

1. Pre-coating of T25 flasks-Add 2 ml of Alphabiocoat (AC001) into a T25 flask to cover the whole surface of the flask. 5 minutes later, remove excessive coating solution by aspiration. Add 5 ml of neutralization solution (NS001). Dispose the excessive neutralization solution by aspiration and the flask is ready for use.

## FOR RESEARCH USE ONLY

NEUROMICS REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. v1-09809

[www.neuromics.com](http://www.neuromics.com)

Neuromics Antibodies • 5325 West 74<sup>th</sup> Street, Suite 8 • Edina, MN 55439  
phone 866-350-1500 • fax 612-677-3976 • e-mail [pshuster@neuromics.com](mailto:pshuster@neuromics.com)

2. Thaw the frozen cell vial in a 37°C water bath first, and then transfer the cells into the pre-coated T25 flask with 10 ml of SF-295 Growth Medium (CCM003), cells usually become confluent with 1-2 days and ready to be passaged.
3. To passage the cells, rinse the cells in a T25 flask with 5 ml HBSS (RT) twice; then add 2 ml Universal Detachment Solution (RT) (AD002) into one T25 flask; gently dispose the excessive Universal Detachment Solution within 20 seconds by aspiration.
4. Leave the T25 flask with the cells at RT or 37°C for 1 min. (Most cells usually will detach from the surface within 1-2 mins.) Otherwise, monitor the cells under a microscope until most of cells become rounded up, and then gently tap the flask against the bench surface, and the cells will move on the surface of the flask.
5. Add 5 ml Universal Neutralization Buffer (NB001) and spin down the cells with 800g centrifugation for 5 mins.
6. Re-suspend the cell pellet with 10 or 15 ml medium and transfer 5 ml each into 2 or 3 pre-coated T25 flasks (for 1/2 to 1/3 subculture ratio).
7. Change medium every 2 or 3 days and the cells usually become confluent within 7 days (when split at a 1/3 ratio).
8. To prepare quiescent cells, when cells are nearly confluent, replace with SF-295 Basal Medium (CCM004) containing 2% FBS for about 8-12hrs.

### FOR RESEARCH USE ONLY

NEUROMICS REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. v1-09809

**[www.neuromics.com](http://www.neuromics.com)**

Neuromics Antibodies • 5325 West 74<sup>th</sup> Street, Suite 8 • Edina, MN 55439  
phone 866-350-1500 • fax 612-677-3976 • e-mail [pshuster@neuromics.com](mailto:pshuster@neuromics.com)